FDA Grants Approval for Signos Glucose Monitoring System in Weight Management Applications

In a groundbreaking development, the U.S. Food and Drug Administration (FDA) has cleared the way for a new over-the-counter continuous glucose monitoring (CGM) system designed for weight management. This innovative device, developed by Signos and led by its CEO and founder, Sharam Fouladgar-Mercer, is set to redefine approaches to weight loss.

The Sisnos CGM system, launched in August 2025, is part of a broader trend towards personalized, preventative health technology. This cutting-edge device offers a data-driven approach to understanding and managing blood sugar levels, providing real-time data on glucose levels through a small sensor worn on the skin.

Beyond its use in diabetes management, the Sisnos CGM system offers valuable insights for individuals attempting weight loss. Stable blood sugar levels are associated with better appetite control, reduced cravings, and less fat storage. With the Sisnos CGM system, users can track their body's response to different diets, such as intermittent fasting, low-carb, or Mediterranean, offering a unique and personalized lens on metabolism.

The Sisnos CGM system also helps users understand how different foods, exercise, sleep patterns, and stress affect blood sugar levels. This understanding can empower individuals to make informed decisions about their diet and lifestyle choices, potentially leading to more effective weight management strategies.

Sharam Fouladgar-Mercer, Signos' co-founder and CEO, emphasizes that the device is available for anyone on a weight loss journey, regardless of the amount of weight to be lost. The Sisnos CGM system sends data directly to a smartphone app, allowing users to instantly view their glucose levels and make informed choices about their diet and exercise.

Medical professionals stress that glucose levels are only one aspect of the weight loss puzzle, alongside calorie balance, hormones, and lifestyle factors. However, the approval of the Sisnos CGM system could reshape approaches to weight loss by offering a more personalized and data-driven method.

The Sisnos CGM system, traditionally used by people with type 1 and type 2 diabetes, is now available for non-diabetic consumers. This widens consumer access, attracting interest among athletes, biohackers, and those looking for a data-driven edge in weight loss.

While the Sisnos CGM system widens consumer access, it's important to note that not everyone will need or benefit from wearable glucose tracking. However, for those seeking a tool to support their weight management efforts, the Sisnos CGM system now offers a valuable resource.

The newly approved Sisnos CGM system is now available for individuals seeking support for weight management, marking a turning point for personalized nutrition and potentially reshaping approaches to weight loss.